Alto Total Cash From Operating Activities vs Total Current Liabilities Analysis
| ANRO Stock | 4.28 0.05 1.15% |
Alto Neuroscience, financial indicator trend analysis is way more than just evaluating Alto Neuroscience, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alto Neuroscience, is a good investment. Please check the relationship between Alto Neuroscience, Total Cash From Operating Activities and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.
Total Cash From Operating Activities vs Total Current Liabilities
Total Cash From Operating Activities vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alto Neuroscience, Total Cash From Operating Activities account and Total Current Liabilities. At this time, the significance of the direction appears to have pay attention.
The correlation between Alto Neuroscience,'s Total Cash From Operating Activities and Total Current Liabilities is -0.94. Overlapping area represents the amount of variation of Total Cash From Operating Activities that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Alto Neuroscience,, assuming nothing else is changed. The correlation between historical values of Alto Neuroscience,'s Total Cash From Operating Activities and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Cash From Operating Activities of Alto Neuroscience, are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Cash From Operating Activities i.e., Alto Neuroscience,'s Total Cash From Operating Activities and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.94 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Total Cash From Operating Activities
Total Current Liabilities
Total Current Liabilities is an item on Alto Neuroscience, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Alto Neuroscience, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Alto Neuroscience,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alto Neuroscience, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.As of the 28th of November 2024, Selling General Administrative is likely to drop to about 6.2 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 50 M
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 114K | 2.3M | 2.7M | 2.8M | Net Interest Income | 114K | 979K | 1.1M | 1.2M |
Alto Neuroscience, fundamental ratios Correlations
Click cells to compare fundamentals
Alto Neuroscience, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Alto Neuroscience,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alto Neuroscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience, will appreciate offsetting losses from the drop in the long position's value.Moving together with Alto Stock
| 0.62 | VALN | Valneva SE ADR | PairCorr |
| 0.66 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.81 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Alto Stock
| 0.77 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.76 | GILD | Gilead Sciences | PairCorr |
| 0.68 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.67 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.59 | PHVS | Pharvaris BV | PairCorr |
The ability to find closely correlated positions to Alto Neuroscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alto Neuroscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alto Neuroscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alto Neuroscience, to buy it.
The correlation of Alto Neuroscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alto Neuroscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alto Neuroscience, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alto Neuroscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.